en.energymedresearch.com
drugs

SYMBICORT ® - Budesonide + Formoterol

SYMBICORT ® is a drug based on Budesonide and Formoterol fumarate dihydrate.

THERAPEUTIC GROUP: Adrenergics for aerosols and other drugs for obstructive airway syndromes

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications SYMBICORT ® - Budesonide + Formoterol

SYMBICORT ® is indicated in patients with asthma or chronic obstructive pulmonary disease where combined corticosteroid and bronchodilator therapy is required.

Mechanism of action SYMBICORT ® - Budesonide + Formoterol

SYMBICORT ® is a medicinal specialty that combines two very important active ingredients, with different but complementary biological activities, particularly active against obstructive respiratory diseases.

More precisely, the high utility of this drug in the treatment of obstructive syndromes is therefore to be correlated to the presence of:

  • Budesonide, a synthetic corticosteroid that is particularly active after topical administration, is effective in controlling the synthesis of inflammatory mediators, such as prostaglandins, prostacyclines, leukotrienes and thromboxanes and therefore the inflammatory degree of the microenvironment.

The well-characterized anti-inflammatory activity is associated with the antiallergic one, probably due on the one hand to the lower recall and activation of circulating basophils partly due to the reduced secretion of pro-allergenic mediators;

  • Formoterol, selective beta 2 adrenergic receptor agonist, capable of selectively interacting with the aforementioned receptors expressed by bronchial smooth muscle, resulting in their activation and consequent relaxation of the bronchial muscles with a clear improvement in ventilatory capacity.

Despite the inhaled administration of the drug, it allows to significantly reduce the systemic absorption of the two active ingredients, it would be opportune to remember how the share of the active principles absorbed through the inflamed mucosa, is rapidly metabolized to the hepatic level and subsequently excreted via the kidney, without compromising the patient's state of health.

Studies carried out and clinical efficacy

BUDESONIDE AND FORMOTEROL IN THE ATHLETIC ASMATIC PATIENT

Thorax. 2013 Oct 3. doi: 10.1136 / thoraxjnl-2013-203557. [Epub ahead of print]

Interesting clinical study that demonstrates how the combination of budesonide and formoterol reduces bronchoconstriction induced by physical exercise, thus improving the clinical conditions of the patient athlete suffering from asthma.

BUEDONIDE AND FORMOTEROL IN THE TREATMENT OF COPD

Respir Med. 2013 Nov; 107 (11): 1709-21. doi: 10.1016 / j.rmed.2013.06.007. Epub 2013 Jul 13.

Study demonstrating that the combined treatment with Budesonide and Formoterol represents a valid therapeutic approach to the treatment of chronic obstructive pulmonary disease, which is also advantageous from an economic point of view.

THERAPIES COMBINED WITH COMPARISON

J Intern Med. 2013 Jun; 273 (6): 584-94. doi: 10.1111 / joim.12067. Epub 2013 Apr 1.

Work demonstrating that the therapeutic combination between Budesonide and Formoterol is more effective than Fluticasone / Salmetrol, guaranteeing a reduction in the symptoms and aggravation of the symptoms present during chronic obstructive pulmonary disease.

Method of use and dosage

SYMBICORT ®

Inhalation powder from 160 mcg of Budesonide and 4.5 mcg of Formoterol fumarate dihydrate by inhalation.

Therapy with SYMBICORT ® must necessarily be established by the doctor based on the physio-pathological characteristics of the patient and the severity of his clinical picture.

For this reason, although we can define as a recommended dose that consisting of 1-2 inhalations twice a day, the doctor should formulate the appropriate dosage of patient in patient, considering in addition to the aforementioned needs also the possibility of a maintenance treatment or of a treatment to need.

Variations in standard dosages are therefore indispensable and unavoidable for the purpose of a correct therapeutic approach to asthmatic or bronchopneumopathic pathology.

Warnings SYMBICORT ® - Budesonide + Formoterol

Therapy with SYMBICORT ® must be preceded by a careful specialist medical examination aimed at clarifying the origin of the symptomatology and any prescriptive appropriateness and by continuous medical supervision useful for monitoring therapeutic success and controlling the potential incidence of side effects.

The clinical objective, besides clearly oriented to the control of symptoms, must necessarily be directed towards the identification of the minimum effective dose, in order to limit as much as possible the incidence of side effects.

Evidently the presence in SYMBICORT ® of a corticosteroid and a beta 2 agonist, exposes the patient, especially the one in prolonged therapy with the drug, to the potential risks and side effects associated with a topical treatment, also requiring the utmost caution for affected patients from cardiovascular diseases, diabetes, hypertension, glaucoma, hyperthyroidism, viral, bacterial and fungal infections.

SYMBICORT ® contains lactose among its excipients, being potentially not indicated in patients with glucose-galactose malabsorption syndrome, lactase enzyme deficiencies and allergies to milk proteins.

The use of SYMBICORT ®, without clinical necessity, is prohibited in and out of the race.

It is recommended to keep the medicine out of the reach of children.

PREGNANCY AND BREASTFEEDING

The absence of studies able to better characterize the safety profile of Formoterol for the health of the fetus and infant, greatly reduce the freedom of use of SYMBICORT ® during pregnancy and in the subsequent period of breastfeeding.

Therefore, the use of this drug in the above periods should be justified by strong clinical needs and continuously monitored by your doctor.

Interactions

Despite the fact that the proportion of active ingredients absorbed is not that relevant, it would still be advisable for the patient on SYMBICORT ® therapy, in order to preserve the efficacy of the therapy and limit the development of potential side effects, to avoid the simultaneous intake of:

  • inducers or inhibitors of liver cytochrome enzyme systems;
  • beta blockers;
  • tricyclic antidepressants and vasoactive amines;
  • monoamine oxidase inhibitors;
  • anticolinegici;
  • digitalis glycosides.

Contraindications SYMBICORT ® - Budesonide + Formoterol

The use of SYMBICORT ® is contraindicated in patients with hypersensitivity to the active ingredient or to one of its excipients, in pregnant and lactating women.

Undesirable effects - Side effects

Therapy with SYMBICORT ® could lead to the appearance of fungal infections of the oropharyngeal tract, sleep disorders, headache, tremor, palpitations, cough, hoarseness and throat irritation.

Fortunately, the incidence of clinically relevant adverse reactions is rare, such as to require the immediate suspension of the therapy in progress.

Note

SYMBICORT ® is a drug subject to mandatory medical prescription.

Interesting Articles